SomaLogic develops and commercializes a proprietary proteomics platform built around its SOMAmer protein-binding reagents, which blend attributes of monoclonal antibodies and traditional aptamers. Its flagship SOMAscan assay currently deploys 1,310 different SOMAmer reagents to quantify proteins across a broad concentration range using small sample volumes from multiple biological matrices. These capabilities provide researchers and clinicians with powerful tools for protein biomarker discovery, diagnostics development, and pharmaceutical innovation. The company is led by Chief Executive Officer Byron Hewett and Founder & Chairman Larry Gold, PhD. SomaLogic plans to expand its portfolio of life-science tools and clinical diagnostic products that leverage its core technology. To finance this growth, it is arranging up to $60.5 million in combined debt and equity financing from Visium Healthcare Partners, strengthening its balance sheet for continued R&D and commercialization efforts.

Total raised

$368M

Funding rounds

7

Latest round

Series A

Latest activity

Dec 2020